VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Thursday, January 8, 2026
Stock Comparison
Boston Scientific Corporation vs Eli Lilly and Company
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Boston Scientific Corporation
BSX · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Boston Scientific Corporation's moat claims, evidence, and risks.
View BSX analysisEli Lilly and Company
LLY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Eli Lilly and Company's moat claims, evidence, and risks.
View LLY analysisComparison highlights
- Moat score gap: Eli Lilly and Company leads (66 / 100 vs 65 / 100 for Boston Scientific Corporation).
- Segment focus: Boston Scientific Corporation has 5 segments (49.8% in Cardiology); Eli Lilly and Company has 5 segments (65.5% in Cardiometabolic Health).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Boston Scientific Corporation has 6 moat types across 3 domains; Eli Lilly and Company has 5 across 2.
Primary market context
Boston Scientific Corporation
Cardiology
Cardiology devices (interventional cardiology, structural heart, electrophysiology, cardiac rhythm management and remote monitoring)
Global
Hospitals/cath labs/EP labs and specialty clinics (cardiologists, electrophysiologists)
Medical device OEM / implantables + procedure devices + service-enabled monitoring
49.8%
Eli Lilly and Company
Cardiometabolic Health
Branded cardiometabolic pharmaceuticals (type 2 diabetes, obesity, and related metabolic/cardiovascular conditions; especially incretin therapies)
Global
Patients via prescribers; payers/PBMs; wholesaler & pharmacy channels
Drug developer, manufacturer, and marketer
65.5%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
Boston Scientific Corporation strengths
Eli Lilly and Company strengths
Segment mix
Boston Scientific Corporation segments
Full profile >Endoscopy
Oligopoly
Urology
Competitive
Neuromodulation
Oligopoly
Cardiology
Oligopoly
Peripheral Interventions
Competitive
Eli Lilly and Company segments
Full profile >Cardiometabolic Health
Oligopoly
Oncology
Competitive
Immunology
Competitive
Neuroscience
Competitive
Other
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.